Comparative effectiveness of antihypertensive drugs in patients with diabetes

Journal of Comparative Effectiveness Research

Volumn 3, Issue 3, 2014, Pages 213-215

  Wu, Hon Yen ^a,b,c   Hung, Kuan Yu ^b   Tu, Yu Kang ^c   Chien, Kuo Liong ^b,c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

angiotensin receptor antagonists; angiotensin converting enzyme inhibitors; Bayes' theorem; diabetes mellitus; drug combinations

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO;

BAYES THEOREM; BLOOD PRESSURE REGULATION; CARDIOMETABOLIC RISK; COMORBIDITY; COMPARATIVE EFFECTIVENESS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIALYSIS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS (TOPIC); MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; COMPLICATION; DIABETES COMPLICATIONS; RISK FACTOR; TREATMENT OUTCOME;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; COMPARATIVE EFFECTIVENESS RESEARCH; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84903581837     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.14.10     Document Type: Review

References (16)

1. Standards of medical care in diabetes-2014. Diabetes Care 37(Suppl. 1), S14-S80 (2014
2. Wu HY, Peng YS, Chiang CK et al. Diagnostic performance of random urine samples using albumin concentration vs ratio of albumin to creatinine for microalbuminuriascreening in patients with diabetes mellitus: A systematic review and meta-Analysis. JAMA Intern. Med. doi:10.1001/jamainternmed.2014.1363 (2014) (Epub ahead of print
3. Wu HY, Huang JW, Lin HJ et al. Comparative effectiveness of renin-Angiotensin system blockers and other antihypertensive drugs in patients with diabetes: Systematic review and Bayesian network meta-Analysis. BMJ 347, f6008 (2013
4. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am. J. Kidney Dis. 60(5), 850-886 (2012
5. Wu HY, Huang JW, Peng YS et al. Microalbuminuria screening for detecting chronic kidney disease in the general population: A systematic review. Ren. Fail. 35(5), 607-614 (2013
6. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311(5), 507-520 (2014
7. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 34(28), 2159-2219 (2013
8. Molitch ME, Defronzo RA, Franz MJ et al. Nephropathy in diabetes. Diabetes Care 27(Suppl. 1), S79-S83 (2004
9. National Institute for Health and Clinical Excellence: Guidance. Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. National Clinical Guideline Centre, London, UK (2011
10. National Institute for Health and Clinical Excellence: Guidance. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). Royal College of Physicians of London, London, UK (2008
11. Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN. Effects of renin-Angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: An updated meta-Analysis. Am. J. Hypertens. 21(8), 922-929 (2008
12. Strippoli GF, Craig M, Schena FP, Craig JC. Antihypertensive agents for primary prevention of diabetic nephropathy. J. Am. Soc. Nephrol. 16(10), 3081-3091 (2005
13. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst. Rev. 4, CD006257 (2006
14. Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst. Rev. 12, CD004136 (2012
15. Wandel S, Juni P, Tendal B et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: Network meta-Analysis. BMJ 341, c4675 (2010
16. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat. Methods Med. Res. 17(3), 279-301 (2008